Literature DB >> 19508681

New imaging approaches to phaeochromocytomas and paragangliomas.

Bas Havekes1, Kathryn King, Edwin W Lai, Johannes A Romijn, Eleonora P M Corssmit, Karel Pacak.   

Abstract

Formerly used concepts for phaeochromocytomas and paragangliomas have been challenged by recent discoveries that at least 24% of tumours are familial and thereby often multiple in various locations throughout the body. Furthermore, tumours are often malignant and perhaps more aggressive if associated with SDHB gene mutations. Some paragangliomas are clinically silent and may present only with dopamine hypersecretion. In the current era where CT and MRI are more commonly used, tumours are more often found as incidentalomas and MRI may be less specific for phaeochromocytoma and paraganglioma than previously thought. Because of unique tumour characteristics (e.g. the presence of cell membrane and intracellular vesicular norepinephrine transporters) these tumours were 'born' to be imaged by means of specific functional imaging approaches. Moreover, additional recent discoveries related to apoptosis, hypoxia, acidosis, anaerobic glycolysis and angiogenesis, often disturbed in tumour cells, open new options and challenges to specifically image phaeochromocytomas and paragangliomas and possibly link those results to their pathophysiology, genotypic alterations and metastatic potential. Functional imaging, especially represented by positron emission tomography (PET), offers an excellent approach by which tumour-specific processes can be detected, evaluated and seen in the context of tumour-specific behaviour and its genetic signature. In this review, we address the recent developments in new functional imaging modalities for phaeochromocytoma and paraganglioma and provide the reader with suggested imaging approaches in various phaeochromocytomas and paragangliomas of sympathetic origin. Current imaging algorithms of head and neck parasympathetic paragangliomas are not discussed. Finally, this review outlines some future perspectives of functional imaging of these tumours.

Entities:  

Mesh:

Year:  2009        PMID: 19508681      PMCID: PMC2966973          DOI: 10.1111/j.1365-2265.2009.03648.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  65 in total

1.  Routine preoperative (123)I-MIBG scintigraphy for patients with phaeochromocytoma is not necessary.

Authors:  Radu Mihai; Fergus Gleeson; Derek Roskell; Andrew Parker; Greg Sadler
Journal:  Langenbecks Arch Surg       Date:  2008-07-29       Impact factor: 3.445

2.  PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma.

Authors:  B L Shulkin; D M Wieland; M Schwaiger; N W Thompson; I R Francis; M S Haka; K C Rosenspire; B Shapiro; J C Sisson; D E Kuhl
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

3.  Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging.

Authors:  B L Shulkin; B Shapiro; I R Francis; R Dorr; S W Shen; J C Sisson
Journal:  Clin Nucl Med       Date:  1986-12       Impact factor: 7.794

4.  Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene.

Authors:  Henri J L M Timmers; Karel Pacak; Thanh T Huynh; Mones Abu-Asab; Maria Tsokos; Maria J Merino; Bora E Baysal; Karen T Adams; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-07       Impact factor: 5.958

5.  Mutations associated with succinate dehydrogenase D-related malignant paragangliomas.

Authors:  Henri J L M Timmers; Karel Pacak; Jérôme Bertherat; Jacques W M Lenders; Michèle Duet; Graeme Eisenhofer; Constantine A Stratakis; Patricia Niccoli-Sire; Ba Huy Patrice Tran; Nelly Burnichon; Anne-Paule Gimenez-Roqueplo
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-31       Impact factor: 3.478

Review 6.  A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).

Authors:  K K Solanki; J Bomanji; J Moyes; S J Mather; P J Trainer; K E Britton
Journal:  Nucl Med Commun       Date:  1992-07       Impact factor: 1.690

7.  Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function.

Authors:  Audrey E T Jacques; Anju Sahdev; Madrika Sandrasagara; Rick Goldstein; Daniel Berney; Andrea G Rockall; Shern Chew; Rodney H Reznek
Journal:  Eur Radiol       Date:  2008-07-19       Impact factor: 5.315

Review 8.  Update on nuclear medicine imaging of neuroendocrine tumors.

Authors:  Stanley J Goldsmith
Journal:  Future Oncol       Date:  2009-02       Impact factor: 3.404

9.  123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.

Authors:  Kunwar S S Bhatia; Mohamed M Ismail; Anju Sahdev; Andrea G Rockall; Kieran Hogarth; Ana Canizales; Norbert Avril; John P Monson; Ashley B Grossman; Rodney H Reznek
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-03       Impact factor: 3.478

10.  Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography.

Authors:  M Schwaiger; V Kalff; K Rosenspire; M S Haka; E Molina; G D Hutchins; M Deeb; E Wolfe; D M Wieland
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

View more
  32 in total

1.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

Review 2.  The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review.

Authors:  Juan P Brito; Noor Asi; Michael R Gionfriddo; Catalina Norman; Aaron L Leppin; Claudia Zeballos-Palacios; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2015-02-06       Impact factor: 3.633

3.  Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

Authors:  Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

4.  The use of functional imaging in a patient with head and neck paragangliomas.

Authors:  Kathryn S King; Millie A Whatley; Dimitrios K Alexopoulos; James C Reynolds; Clara C Chen; Douglas E Mattox; Sol Jacobs; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2010-02       Impact factor: 5.958

Review 5.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

6.  Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype.

Authors:  Vincent Amodru; Carole Guerin; Sarkis Delcourt; Pauline Romanet; Anderson Loundou; Bruna Viana; Thierry Brue; Frédéric Castinetti; Frédéric Sebag; Karel Pacak; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-16       Impact factor: 9.236

7.  Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes.

Authors:  Victoria L Martucci; Zarina G Lorenzo; Michael Weintraub; Jaydira del Rivero; Alexander Ling; Maria Merino; Minhaj Siddiqui; Brian Shuch; Srinivas Vourganti; W Marston Linehan; Piyush K Agarwal; Karel Pacak
Journal:  Urol Oncol       Date:  2015-02-13       Impact factor: 3.498

Review 8.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

9.  Transurethral resection of bladder tumour (TURBT) as an optional treatment method on pheochromocytoma of the urinary bladder.

Authors:  Sun Gook Ahn; Hoon Jang; Dong Seok Han; Jung Uee Lee; Seung Mo Yuk
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

10.  PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma.

Authors:  Ingo Janssen; Clara C Chen; Corina M Millo; Alexander Ling; David Taieb; Frank I Lin; Karen T Adams; Katherine I Wolf; Peter Herscovitch; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.